The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health crisis. Human
neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the …

Neutralizing antibody responses to coronaviruses mainly target the receptor-binding
domain (RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) …

Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in
individuals who develop high titers of anti-ZIKV antibodies, we screened cohorts in Brazil and …

HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which
broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the …

Some HIV-1–infected patients develop broad and potent HIV-1 neutralizing antibodies (bNAbs)
that when passively transferred to mice or macaques can treat or prevent infection. …

The HIV-1 envelope (Env) glycoprotein, a trimer of gp120–gp41 heterodimers, relies on
conformational flexibility to function in fusing the viral and host membranes. Fusion is achieved …

Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal
models, suggesting that a vaccine that elicits these antibodies would be protective in humans. …

Soluble forms of angiotensin-converting enzyme 2 (ACE2) have recently been shown to
inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We report on …

Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and
treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope …

Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1
vaccine design efforts. Developing bNAbs with increased efficacy requires understanding …